NEW DEHLI, INDIA – After failing to fulfill India’s pharmaceutical regulator’s requirement for a local safety and immunogenicity study, Pfizer reportedly withdrew its application for emergency-use authorization of its COVID jab in the country, per a company statement delivered on February 4th.
As a result of the decision, Pfizer’s COVID shot will not be available for purchase in the foreseeable future in neither India nor China, two of the most populated nations in the world. Apparently both countries have gone a different route when it pertains to their breed of COVID jabs being administered.
The backstory on Pfizer pulling out of trying to break into the India market is a unique one, as the company had apparently sought to bypass standard procedures that other COVID jab developers had to adhere to when being placed on the market in India.
